Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner.

4d pharma reports ‘encouraging’ results for new asthma drug

Aberdeen is home to much of 4D pharma's drug research and development
Aberdeen is home to much of 4D pharma's drug research and development

Life sciences firm 4D pharma has announced “encouraging” results from an early-stage trial of an asthma drug.

A total of 34 patients were enrolled for the first part of 4D pharma’s phase I/II study of MRx-4DP0004, with half being given the new drug and the other half receiving a placebo.

No serious adverse reactions were reported during the trial, which 4D pharma said “generated promising signals of clinical activity”.

The second part of the study is expected to involve up to 90 patients.

For a study of this size in a relatively mild and heterogeneous population the signals are encouraging.”

Alex Stevenson, 4D pharma.

Alex Stevenson, 4D pharma’s chief scientific officer, said the “part “A” test results were “an important step forward in our development of a new safe oral therapeutic for asthma patients”.

He added: “MRx-4DP0004 has shown encouraging activity in key secondary endpoints of clinical activity.

“This data will help to guide the selection of patients for future development of the product.

“For a study of this size in a relatively mild and heterogeneous population, the signals are encouraging.”

4D pharma is focused on live biotherapeutics, a relatively new group of medicines that use bacteria in the human body to tackle disease.

As well as helping digestion and the production of vitamins, these bacteria have an important role in regulating the immune and central nervous systems.

London-listed 4D pharma, which grew out of Aberdeen University Rowett Institute spinout GT Biologics, says its medical potential goes way beyond treatments for gastrointestinal conditions such as irritable bowel syndrome and Crohn’s disease.

Labwork being undertaken by biotechnology firm 4D pharma.

More than 30 researchers are involved in the discovery and pre-clinical testing of drugs in 4d pharma’s Aberdeen operation, at Foresterhill, although the company’s head office is in Leeds.

MRx-4DP0004 has been shown to significantly reduce lung inflammation and deliver other benefits in asthma, as well as multiple sclerosis and rheumatoid arthritis patients.

Asthma affects 300 million people globally, with between 5-10% of sufferers having a severe form of the disease.

According to 4d pharma, there is a growing body of evidence linking the gut microbiome to the development of asthma.

The global asthma therapeutics market is projected to reach £17.4 billion by 2023.


Opportunity North East accelerates more life sciences research spin-outs

Researcher at Aberdeen life sciences firm Elasmogen lands £2m fellowship

Already a subscriber? Sign in

[[title]]

[[text]]